when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

ELI LILLY CO · news · pharmadog

← back to ELI LILLY CO

News mentioning ELI LILLY CO

630 stories

Jul 9, 26STAT+: Pharmalittle: We’re reading about FDA commissioner contenders, a heart drug failure, and morestat

Jul 9, 26Opinion: Who benefits from classifying obesity as a disease?stat

Jul 8, 26Biohaven looks to take on Lilly in the muscle-sparing obesity spaceendpoints

Jul 8, 26STAT+: Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and morestat

Jul 7, 26Tampa General kicks off legal fight over Lilly's 340B restrictionsendpoints

Jul 7, 26Oberland pours up to $400M into MeiraGTx eye gene therapiesbiopharma dive

Jul 7, 26Kailera says obesity pill succeeds in late-stage trial in Chinabiopharma dive

Jul 7, 26STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and morestat

Jul 6, 26Gene editing developer Scribe plots an IPObiopharma dive

Jul 6, 26Novartis to acquire ADC developer in a deal worth up to $1.5Bbiopharma dive

Jul 6, 26STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and morestat

Jul 2, 26STAT+: Medicare takes another swing at 340B cuts to hospitalsstat

Jul 2, 26STAT+: Lawmakers urge HHS to force Eli Lilly to provide 340B drug discounts to hospitalsstat

Jul 2, 26STAT+: Elevance sues government over $115 million tied to Medicare Advantage star ratingsstat

Jul 2, 26STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and morestat

Jul 2, 26The new presidential fitness test is a positive step, not the solution, experts saystat

Jul 1, 26STAT+: Booze schmooze: The alcohol industry, frazzled by headwinds, wields its power behind the scenesstat

Jun 30, 26Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot programbiopharma dive

Jun 30, 26Republican Tom Kean Jr. reveals depression diagnosis after his four-month absence from Congressstat

Jun 30, 26Eli Lilly, Fujifilm among seven selected for FDA’s PreCheck pilotendpoints

Jun 30, 26These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.biopharma dive

Jun 30, 26Half of states sue over Medicaid work requirementsstat

Jun 30, 26STAT+: Even with MAHA, Trump administration has gone soft on alcoholstat

Jun 30, 26STAT+: The loophole in Trump’s obesity drug deal with Eli Lilly and Novo Nordiskstat

Jun 29, 26FDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug Manufacturingfda press

Jun 29, 26STAT+: 26 states sue to block Medicaid work requirementsstat

Jun 29, 265 takeaways from STAT’s investigation into microhospital operator Nutex Healthstat

Jun 29, 26STAT+: Longevity, wellness physicians named to panel advising FDA on peptidesstat

Jun 29, 2610 clinical trials to watch in the second half of 2026biopharma dive

Jun 26, 26FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences servicesbiopharma dive

← prevpage 17 of 21next →